MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

HPi1

CAS No. : 13080-21-2

MCE 国际站：HPi1

产品活性：HPi1 是一种针对幽门螺杆菌 (Helicobacter pylori) 的有效，选择性和具有口服活性的抗菌剂，IC₅₀ 为 0.24 μM，MIC 为 0.08-0.16 μg/mL。HPi1 对其他细菌无活性，包括肠道菌干酪乳杆菌，罗伊氏乳杆菌和长双歧杆菌。

研究领域：Anti-infection

作用靶点：Bacterial

In Vitro: The MIC against H. pylori isolates ranged from 0.002-0.032 μg/mL (0.01-0.17 μM) in the agar dilution assay. HPi1 is effective against the clarithromycin-resistant strains ARHp172 (MIC of 0.004–0.016 μg/mL) and ARHp246 (MIC of 0.008–0.032 μg/mL).
HPi1 has some activity against the Bacteroides species, but at concentrations at least 18-fold higher than the H. pylori MIC. More potent activity is detected for Campylobacter jejuni with an MIC of 0.3 μg/mL.
HPi1 has good physicochemical and pharmacological properties, including determining the aqueous solubility (19 μg/mL), human plasma protein binding (93% bound), stability with human liver microsomes (T_1/2 of 1.3 hours) and the ability to passively permeate membranes.

In Vivo: HPi1 (6.25-50 mg/kg; Oral gavage; once a day; for 3 days; female C57BL/6 mice) treatment decreases colony counts below the limit of detection at doses of 25 or 50 mg/kg/day.

相关产品：Bioactive Compound Library Plus  |  Rapamycin  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Dexamethasone  |  Puromycin dihydrochloride  |  Dimethyl sulfoxide  |  Staurosporine  |  Actinomycin D  |  G-418 disulfate  |  Etoposide  |  5-Azacytidine  |  Nigericin sodium salt  |  Brefeldin A  |  Estradiol  |  CCCP  |  Ionomycin  |  Resveratrol  |  Hygromycin B  |  Tunicamycin  |  Mitomycin C  |  Everolimus  |  Doxycycline hyclate  |  Tacrolimus  |  Methotrexate  |  Neomycin sulfate  |  Acetaminophen  |  Streptozotocin  |  Anisomycin  |  Cholesterol

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds